Phi Pharma SA is developing a new class of anti-cancer drugs: peptide drug conjugates effective in multiple human cancers using an innovative mechanism of cell entry: novel sugar-based drug targets.
-
Swiss Biotech AssociationNot a member
- Claim / update listing